Economic Evaluation in Genomic and Precision Medicine provides an in-depth examination of essential concepts, protocols and applications of economic evaluation in genomic and precision medicine. Contributions from leading international medical geneticists and health economists compile new ways to effectively assess the costs and outcomes of different genomic care pathways, implement cost-effective medical interventions, and enhance the value of genomic and precision healthcare. Foundational chapters and discipline-specific case studies cover topics ranging from the economic analysis of genomic trial design, to health technology assessment of next-generation sequencing, ethical aspects, economic policy in genomic medicine, and pricing and reimbursement in clinical genomics.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Introduction to economic evaluation in health sciences 2. Foundations of pharmacogenomics and personalized medicine 3. Economic evaluation of genome-guided treatment in oncology 4. Economic evaluation of rare diseases and the diagnostic odyssey 5. Economic analysis of pharmacogenetic testing for HLA-based adverse drug reactions 6. Economic evaluation of personalized medicine interventions in medium- and low-income countries with poor proliferation of genomics and genetic testing 7. Theoretical models for economic evaluation in genomic and personalized medicine 8. Using big data in economic evaluations in genomics: Challenges and opportunities 9. Assessing the stakeholder environment and views towards implementation of personalized medicine in a healthcare setting 10. Feasibility for pricing, budget allocation, and reimbursement of personalized medicine interventions
Authors
Christina Mitropoulou Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized Medicine.
Christina Mitropoulou is Managing Director and Principal Investigator at the Golden Helix Foundation (London, UK), a registered UK-Charity with Research and Educational activities in the field of Genomic and Personalized Medicine. Her research interests revolve around the health economic evaluation of genome-guided therapeutic interventions. Also, Christina Mitropoulou participates as Executive Committee member of the Ubiquitous Pharmacogenomics (U-PGx) project and coordinates the health economic evaluation of the PREPARE clinical study on pre-emptive Pharmacogenomics testing, involving approx. 8000 patients from 7 clinical sites and she is an active member of the Pharmacogenomics Access and Reimbursement Coalition. Christina Mitropoulou has published several original articles on this topic in leading scientific journals and has edited two textbooks on economic evaluation in Genomic Medicine that are published by Elsevier/Academic Press.
Sarah Wordsworth University of Oxford, Medical Sciences Division, Nuffield Department of Population Health, Oxford, UK.
Sarah Wordsworth is at the University of Oxford, Medical Sciences Division, Nuffield Department of Population Health, Oxford, UK.
James Buchanan Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
James Buchanan PhD joined the Health Economics Research Centre in 2005 and works predominantly on projects examining the economics of translating genomic high-throughput technologies from research into clinical practice, especially in cancer and infectious disease. In 2011 he was awarded a National Institute for Health Research Doctoral Research Fellowship to undertake a PhD in Health Economics investigating issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating a targeted array in haematological cancers. Previous genomics projects include an economic evaluation of the use of genetic testing to identify the somatic mutations that can cause common cancers, an economic evaluation of the use of genetic tests to identify gastrointestinal pathogens to improve hospital infection control practice, the development of an economic modelling framework to evaluate novel genomic diagnostic tools in inflammatory bowel disease, and a cost-effectiveness analysis of microarray technology in the UK National Health Service. His other interests include costing methodology and the valuation of patient preferences. He also teaches on a range of undergraduate and postgraduate courses at the University of Oxford, and teaches advanced cost-effectiveness analysis methods to health economists and policy makers.
George P. Patrinos Department of Pharmacy, University of Patras School of Health Sciences, Patras, Greece; United Arab Emirates University, College of Medicine and Health Sciences, Department of Pathology, Al-Ain, UAE and Erasmus University Medical Center, School of Medicine and Health Sciences, Department of Pathology - Bioinformatics Unit, Rotterdam, The Netherlands.
Dr. George Patrinos is an Associate Professor at the University of Patras School of Health Sciences (Department of Pharmacy) in Patras, Greece with Adjunct positions in Rotterdam, the Netherlands and Al-Ain, United Arab Emirates. His research interests span the fields of molecular diagnostics, high-throughput mutation screening, the development of online mutation diagnostic tools, and the implementation of genomics into healthcare, particularly for health systems in developing countries. George Patrinos has published more than 170 scientific papers in peer reviewed journals on topics related to genetics, genomic medicine, pharmacogenomics, molecular diagnostics, and social and economic evaluation for genomic medicine. Dr. Patrinos is also the co-author of Economic Evaluation in Genomic Medicine (2015) and co-Editor of Molecular Diagnostics, Second Edition (2009), both published by Elsevier, and serves as Communicating Editor for the journal Human Mutation. Additionally, he is co-organizer of the international meeting series "Golden Helix Symposia and "Golden Helix Pharmacogenomics Days.
